Market Cap 304.90M
Revenue (ttm) 30,000.00
Net Income (ttm) -51.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -172,100.01%
Debt to Equity Ratio 0.00
Volume 556,500
Avg Vol 1,139,262
Day's Range N/A - N/A
Shares Out 147.29M
Stochastic %K 100%
Beta 2.48
Analysts Strong Sell
Price Target $8.29

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 3641 508 180
Address:
Winzerlaer Str. 2, Jena, Germany
Sterphanise
Sterphanise Aug. 19 at 5:02 AM
$IFRX No huge change, but Commodore Capital LP has reported yesterday via 13G that they own now 5,1% of the outstanding IFRX shares. For 30 June they have reported 7.300.000 shares and for 10 August they have reported 7.475.000 shares. (~4,95% to 5,1%) https://fintel.io/so/us/ifrx
0 · Reply
Barkingdogs
Barkingdogs Aug. 19 at 1:21 AM
$IFRX IFRX a number of things can happen to spike the stock suddenly including Test results in trial China connection news Possible partner Takeover attempt Raise the 250 million that was just filed And a breakout on volume will bring in THe SHORTS 🤑🤑🤑😄itsa buy
0 · Reply
Holten7575
Holten7575 Aug. 18 at 8:02 PM
$IFRX step by step --green in a see of red
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 7:40 PM
$IFRX how long will shorts wait to cover?? 2.40 plus on volume lookout! 🤑🤑
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 7:14 PM
$IFRX what's Izicopan worth???? More than 300 million???mkt cap Of course Itsa buy🤑🤑🤑
0 · Reply
Jdorkshire
Jdorkshire Aug. 18 at 5:33 PM
$IFRX It appears we have entered buyers land
1 · Reply
Yoyo35
Yoyo35 Aug. 18 at 4:18 PM
$IFRX Slow accumulation until Oct 8th CMD?
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 1:38 PM
$IFRX don't forget the short squeeze!!!! 💪
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 1:28 PM
$IFRX a number of things can happen to spike the stock suddenly including Test results in trial China connection news Possible partner Takeover attempt Raise the 250 million that was just filed 🤑🤑🤑
1 · Reply
Holten7575
Holten7575 Aug. 18 at 11:46 AM
$IFRX As an example of why price isn’t going anywhere anytime soon. Only real institutional stability that I see is through the Montanova and TCG ---------care to disagree ---tutes are buying low---investors are slowly adding here --it may be a slow crawl but its crawling (i like it that way) --building a firm base --there will come a time when you look back and say --i could have got it for $2.00
0 · Reply
Latest News on IFRX
InflaRx Earnings release: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 12 days ago

InflaRx Earnings release: Q2 2026


InflaRx files $250M mixed securities shelf

2026-08-06T13:26:42.000Z - 12 days ago

InflaRx files $250M mixed securities shelf


InflaRx Registration statement: Registration filing

Aug 6, 2026, 8:00 AM EDT - 13 days ago

InflaRx Registration statement: Registration filing


InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Jul 30, 2026, 7:30 AM EDT - 20 days ago

InflaRx to Report Second Quarter 2026 Results on August 6, 2026


InflaRx upgraded to Strong Buy from Outperform at Raymond James

2026-05-13T12:32:38.000Z - 3 months ago

InflaRx upgraded to Strong Buy from Outperform at Raymond James


InflaRx price target raised to $8 from $6 at H.C. Wainwright

2026-05-11T18:30:06.000Z - 3 months ago

InflaRx price target raised to $8 from $6 at H.C. Wainwright


InflaRx Transcript: Investor update

May 8, 2026, 8:30 AM EDT - 3 months ago

InflaRx Transcript: Investor update


InflaRx Press release: Investor update

May 8, 2026, 8:30 AM EDT - 3 months ago

InflaRx Press release: Investor update


InflaRx Slides: Investor update

May 8, 2026, 8:30 AM EDT - 3 months ago

InflaRx Slides: Investor update


InflaRx to develop izicopan in AAV

2026-05-07T03:51:29.000Z - 3 months ago

InflaRx to develop izicopan in AAV


InflaRx announces new izicopan pre-clinical data

2026-05-04T12:09:26.000Z - 3 months ago

InflaRx announces new izicopan pre-clinical data


InflaRx to Report First Quarter 2026 Results on May 7, 2026

May 1, 2026, 7:30 AM EDT - 3 months ago

InflaRx to Report First Quarter 2026 Results on May 7, 2026


InflaRx assumed with an Outperform at Oppenheimer

2026-04-24T11:41:38.000Z - 4 months ago

InflaRx assumed with an Outperform at Oppenheimer


InflaRx announces new izicopan in vitro findings

2026-04-09T11:54:44.000Z - 4 months ago

InflaRx announces new izicopan in vitro findings


InflaRx presents vilobelimab data

2026-03-30T12:10:23.000Z - 5 months ago

InflaRx presents vilobelimab data


InflaRx price target lowered to $14 from $22 at Guggenheim

2026-03-20T11:20:14.000Z - 5 months ago

InflaRx price target lowered to $14 from $22 at Guggenheim


InflaRx Annual report: Q4 2025

Mar 19, 2026, 9:30 AM EDT - 5 months ago

InflaRx Annual report: Q4 2025


InflaRx Earnings release: Q4 2025

Mar 19, 2026, 9:30 AM EDT - 5 months ago

InflaRx Earnings release: Q4 2025


InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

2026-03-19T11:35:54.000Z - 5 months ago

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year


InflaRx to Report Full Year 2025 Results on March 19, 2026

Mar 12, 2026, 7:30 AM EDT - 5 months ago

InflaRx to Report Full Year 2025 Results on March 19, 2026


InflaRx Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 5 months ago

InflaRx Transcript: Leerink Global Healthcare Conference 2026


InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:53:16.000Z - 9 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink


InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:16:16.000Z - 9 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink


InflaRx price target raised to $8 from $3 at Cantor Fitzgerald

2025-11-11T11:20:32.000Z - 10 months ago

InflaRx price target raised to $8 from $3 at Cantor Fitzgerald


InflaRx price target raised to $9 from $2 at Raymond James

2025-11-11T11:16:27.000Z - 10 months ago

InflaRx price target raised to $9 from $2 at Raymond James


InflaRx price target raised to $7 from $3 at Oppenheimer

2025-11-11T11:15:24.000Z - 10 months ago

InflaRx price target raised to $7 from $3 at Oppenheimer


InflaRx Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 10 months ago

InflaRx Earnings release: Q3 2025


InflaRx Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

InflaRx Transcript: Status Update


InflaRx Press release: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

InflaRx Press release: Status Update


InflaRx Slides: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

InflaRx Slides: Status Update


InflaRx Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:10 AM EDT - 1 year ago

InflaRx Transcript: Cantor Global Healthcare Conference 2025


InflaRx Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

InflaRx Earnings release: Q2 2025


InflaRx to Participate in Upcoming Investor Conferences

May 22, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Upcoming Investor Conferences


InflaRx Earnings release: Q1 2025

May 7, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q1 2025


InflaRx to Report First Quarter 2025 Results on May 7, 2025

Apr 30, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025


InflaRx Earnings release: Q4 2024

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q4 2024


InflaRx Annual report: Q4 2024

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Annual report: Q4 2024


InflaRx Earnings release: Q3 2024

Nov 8, 2024, 9:30 AM EST - 1 year ago

InflaRx Earnings release: Q3 2024


InflaRx Announces Participation in September Investor Events

Aug 27, 2024, 7:30 AM EDT - 2 years ago

InflaRx Announces Participation in September Investor Events


InflaRx Earnings release: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

InflaRx Earnings release: Q2 2024


InflaRx Hosts R&D Event Highlighting the Promise of INF904

Jun 5, 2024, 12:00 PM EDT - 2 years ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904


Sterphanise
Sterphanise Aug. 19 at 5:02 AM
$IFRX No huge change, but Commodore Capital LP has reported yesterday via 13G that they own now 5,1% of the outstanding IFRX shares. For 30 June they have reported 7.300.000 shares and for 10 August they have reported 7.475.000 shares. (~4,95% to 5,1%) https://fintel.io/so/us/ifrx
0 · Reply
Barkingdogs
Barkingdogs Aug. 19 at 1:21 AM
$IFRX IFRX a number of things can happen to spike the stock suddenly including Test results in trial China connection news Possible partner Takeover attempt Raise the 250 million that was just filed And a breakout on volume will bring in THe SHORTS 🤑🤑🤑😄itsa buy
0 · Reply
Holten7575
Holten7575 Aug. 18 at 8:02 PM
$IFRX step by step --green in a see of red
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 7:40 PM
$IFRX how long will shorts wait to cover?? 2.40 plus on volume lookout! 🤑🤑
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 7:14 PM
$IFRX what's Izicopan worth???? More than 300 million???mkt cap Of course Itsa buy🤑🤑🤑
0 · Reply
Jdorkshire
Jdorkshire Aug. 18 at 5:33 PM
$IFRX It appears we have entered buyers land
1 · Reply
Yoyo35
Yoyo35 Aug. 18 at 4:18 PM
$IFRX Slow accumulation until Oct 8th CMD?
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 1:38 PM
$IFRX don't forget the short squeeze!!!! 💪
0 · Reply
Barkingdogs
Barkingdogs Aug. 18 at 1:28 PM
$IFRX a number of things can happen to spike the stock suddenly including Test results in trial China connection news Possible partner Takeover attempt Raise the 250 million that was just filed 🤑🤑🤑
1 · Reply
Holten7575
Holten7575 Aug. 18 at 11:46 AM
$IFRX As an example of why price isn’t going anywhere anytime soon. Only real institutional stability that I see is through the Montanova and TCG ---------care to disagree ---tutes are buying low---investors are slowly adding here --it may be a slow crawl but its crawling (i like it that way) --building a firm base --there will come a time when you look back and say --i could have got it for $2.00
0 · Reply
mconnell
mconnell Aug. 18 at 1:38 AM
0 · Reply
Barkingdogs
Barkingdogs Aug. 17 at 9:02 PM
$IFRX Commodore Capital bought 7.5 million shares 🤑🤑🤑
0 · Reply
Barkingdogs
Barkingdogs Aug. 17 at 6:55 PM
$IFRX read this
1 · Reply
MrCompassion
MrCompassion Aug. 17 at 6:49 PM
$IFRX Farallon Capital Management held (fact vs “currently holds” wishful thinking) 3,325,000 IFRX shares as of the 6/30/2026 event date: https://www.sec.gov/Archives/edgar/data/909661/000090883426000421/xslSCHEDULE_13G_X02/primary_doc.xml But their filing for the 5/7/2026 event date listed a total of 7,500,000 shares spread over eight separate pools of client money. https://www.sec.gov/Archives/edgar/data/1175707/000090883426000234/xslSCHEDULE_13G_X02/primary_doc.xml 4,175,000 shares sold in under two months. As an example of why price isn’t going anywhere anytime soon. Only real institutional stability that I see is through the Montanova and TCG holdings, top two. Maybe Sirenia plans to stick around for a bit considering their odd total holding of 8,911,348 shares, suggesting they have added to their original @$2 buy. Then there's InflaRx's $65M ATM filed 8/14; the company itself able to sell into any strength.. https://www.sec.gov/Archives/edgar/data/1708688/000114036126033149/ny20075001x3_424b5.htm No real data catalysts for months to come. Start of AAV p3? So what. Start of POCs? That’s not data. Don’t expect fireworks anytime soon. But as long as old-Suvretta sticks around, I’m in ;)
4 · Reply
Barkingdogs
Barkingdogs Aug. 17 at 6:38 PM
$IFRX herein is
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Aug. 17 at 2:26 PM
$IFRX Sorry if this has already been posted. A separate Phase 1 study of izicopan (INF904) is registered in the European CTIS. Using carbon-14-labelled izicopan, the study investigates how the drug is metabolized and eliminated in humans and which metabolites are formed. It includes 8 healthy male participants, started on May 4, 2026, and had a planned end date of June 19, 2026. [CTIS study record] (https://euclinicaltrials.eu/ctis-public/view/2026-525517-31-00?utm.com) Important, This is a separate clinical ADME study in humans, distinct from the mechanistic and reactive-metabolite work reported by InflaRx in April/May 2026. I have not found a separate InflaRx announcement for this study or any publicly available results so far. - Based on the currently publicly available information; no guarantee of completeness. -
2 · Reply
Barkingdogs
Barkingdogs Aug. 17 at 1:15 PM
$IFRX bow wow get ready ..the story is obviously out ...this is a big one 🤑🤑🤑
0 · Reply
otcgtc
otcgtc Aug. 17 at 10:46 AM
$IFRX ...
1 · Reply
Barkingdogs
Barkingdogs Aug. 17 at 2:18 AM
$IFRX 2.40 critical breakout with volume
0 · Reply
rusi1
rusi1 Aug. 16 at 2:53 PM
$IFRX i hope not so, but can this compay make inflarx troubles? Swedish Orphan Biovitrum
1 · Reply
levystrauss
levystrauss Aug. 16 at 2:15 PM
$IFRX Nelsa ridmen
0 · Reply
NYBomba
NYBomba Aug. 15 at 6:55 PM
$IFRX - short interest link below; if you click the 1-year chart, it shows a huge improvement compared to the precarious months from Nov 25 to March 26... looks like institutional holdings have increased and the only short interest is retail ... IMO there's nothing to worry about unless do-do happens... https://www.iborrowdesk.com/report/IFRX
0 · Reply